This protocol is for patients with plaque psoriasis who have concomitant psoriatic arthritis — a presentation where joint and skin involvement co-exist and must be addressed together in the treatment plan.
The presence of psoriatic arthritis alongside plaque psoriasis significantly influences which biologic agent is selected. Among available biologic options, a specific class of agents is considered the preferred choice for patients with this combined presentation, given the need to manage both skin burden and active joint disease.
The preferred biologic strategy for plaque psoriasis with concomitant psoriatic arthritis involves initiating a TNF-α inhibitor — a class with long-established efficacy and regulatory approval in this combined setting. The specific agent, full sequencing, and regimen details are available in the complete protocol.
Treatment aims for a 75% improvement in the Psoriasis Area Severity Index (PASI 75) alongside measurable improvement in psoriatic arthritis signs and symptoms. A definitive assessment of response is generally made after 12 to 16 weeks of continuous therapy.
DOI: 10.1016/j.jaad.2018.11.057
Among the biologics TNF-a inhibitors should be considered as a preferred treatment option for patients with concomitant PsA.
All TNF-a inhibitors have long-established efficacy and FDA approval for PsA.
Definitive response (positive or negative) to treatment with most TNF-a inhibitors is best ascertained after 12 to 16 weeks of continuous therapy, except for infliximab, for which the best time is after 8 to 10 weeks.
View source ↗